近日,上市透明质酸龙头华熙生物旗下公司华熙唐安宣布,正式与深圳光明的国家生物制造产业创新中心签约合作,建立了全球首个非动物源肝素全产业链平台。据悉,该公司通过全酶法体外合成肝素,其抗凝血活性较动物源肝素提升10倍,同步构建固定化酶法连续自动化生产体系,时空转化率较游离酶体系提升百倍以上,有望打破动物资源依赖与安全隐患。我们熟悉的胰岛素、青蒿素最早都是从相关的动物或植物中提取,传统化学方法难以实现...
Source Link近日,上市透明质酸龙头华熙生物旗下公司华熙唐安宣布,正式与深圳光明的国家生物制造产业创新中心签约合作,建立了全球首个非动物源肝素全产业链平台。据悉,该公司通过全酶法体外合成肝素,其抗凝血活性较动物源肝素提升10倍,同步构建固定化酶法连续自动化生产体系,时空转化率较游离酶体系提升百倍以上,有望打破动物资源依赖与安全隐患。我们熟悉的胰岛素、青蒿素最早都是从相关的动物或植物中提取,传统化学方法难以实现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.